Evidence, Access & Pricing:
Pricing & Access
Our team of Pricing & Access experts work across functions to leverage locally-nuanced but comprehensively global, value-based pricing and market access strategies.
Evidence, Access & Pricing:
Our team of Pricing & Access experts work across functions to leverage locally-nuanced but comprehensively global, value-based pricing and market access strategies.
Trinity supports pricing strategy at all phases of development to support a product’s access and commercial success, including pre-clinical prioritization, launch pricing and lifecycle management.
A nuanced understanding of Pricing & Access issues is needed to support other types of work, including Strategic Advisory offerings (e.g., corporate strategy, strategic product planning and business development support), and Commercial Analytics (e.g., forecasting).
Trinity has extensive experience working with cross-functional decision makers to provide a detailed understanding of how Pricing & Access dynamics, such as gross price, net price, reimbursement policy and emerging marketplace developments impact commercial success.
Constructing and evolving contracting strategy is challenging. There are many scenarios and variables to evaluate when establishing the placement and targeting of contract value and investment. Each option requires unique inputs and models—and each scenario has a range of potential impacts on stakeholders, from internal finance teams to payers and providers.
Contracts have both direct and indirect impacts on ASP (Average Sales Price), Reimbursement, 340B price and Medicaid rebates. Each of these elements could then impact product demand, net revenue, net price per unit and breakeven ROI contract targets—with the indirect costs having greater impact than direct contracting costs in certain situations.
The central question is how to quickly evaluate and quantify the holistic impact of contracting decisions to arrive at the optimal contract strategy and avoid making mistakes that cannot be rectified down the line.
Crafting impactful contract strategy requires expertise in life sciences and deep U.S. payer, provider, government policy, regulatory, distribution and finance knowledge.
Trinity’s Contract Analytics offering provides advisory services powered by Trinity CloudCast™, a cloud-based modeling and analytics tool.
Clients are able to:
Clients navigate U.S. pricing, contracting, provider economics and Gross-To-Net (GTN) decision-making by understanding the impact of individual contract strategies through expertly curated insights, unlimited scenario analysis (unlimited number of contracts and channel types) and accurate, comprehensive financial forecasting/modeling.
The contracting process is streamlined by forecasting the impact of changes in Wholesale Acquisition Cost (WAC) and other contracting elements including GTN, Average Sales Price (ASP), 340B and Medicaid considerations.
Contract Analytics integrates with Trinity’s Payer/Pricing Strategy, Contracting Strategy, Forecasting and Payer Analytics offerings to provide cross-functional support, establish KPIs to track ROI and evaluate risk across an asset’s market access journey.
Trinity helps brands to maximize their place in the market by developing and pressure testing pricing plans and gathering or generating strong supporting evidence. We offer a complete solution, from a high-level strategic pricing plan all the way to detailed tactics about specific discounts and offer structures.
Our clients benefit from leveraging Trinity’s quality global research panel, giving us a unique ability to gather nuanced insights about pricing specifics for each country or payer type on a peer-to-peer level.
Each year we conduct pricing research with a wide range of customer types, including:
Additionally, the features and strategic issues at hand span across a wide range of permutations:
We support clients’ contracting efforts from early assessment to strategy development, execution support and reporting / performance measurement. Trinity’s holistic services include support with contracting and tendering with both U.S. and global payers, as well as U.S. providers.
While a large portion of our contracting work can be considered ‘traditional’, we also support clients who are considering innovative contracting approaches, such as outcomes-based or other value-based arrangements. Whatever your need, Trinity’s strategic support is holistic and end to end.
OUR APPROACH
Through collaborative working sessions, detailed account data analysis, and robust economic modeling, we can determine the optimal strategy to help our clients overcome value deficiencies.
Payer Contracting:
We guide our clients to establish a net price to optimize physician and patient access. Global net price strategies seek to balance price maintenance with access attainment, often considering multiple indications or populations. Meanwhile, U.S. managed care rebate strategies are structured to optimize to formulary positioning and mitigate barriers associated with utilization management.
The Trinity Difference:
Provider Contracting Expertise:
Trinity has a deep understanding of provider economics and how to optimize provider contracting to shape decision-making and ensure access while maintaining value.
The Trinity Difference:
The access landscape is changing; cross-border collaborations are forming to better support accelerated access to high-cost and orphan therapies, new policies are in development to address the healthcare disparities that have been highlighted during the COVID-19 pandemic, and innovative pricing and reimbursement approaches are being implemented to ensure the latest advances in healthcare technologies reach growing patient populations globally.
Access Analyzer provides the ability to track and monitor performance by plan and payer.
The solution suite offers digitization, proprietary frameworks and algorithms, nearly instant value and in-depth dataset knowledge:
Access Analyzer delivers results:
Our experts monitor access trends and policy changes to inform landscape assessments and help our clients understand access expectations, including collaboration opportunities to gain early HTA advice to secure better outcomes and nuanced market access timelines by region.
The Trinity Difference:
Our experts understand the need for simplicity in supply chain decision-making and management. We help our clients to determine the optimal distribution strategies to reduce time-to-patient, ensure efficiency around arranging distribution to trade partners, and secure cost-effective distribution solutions.
The Trinity Difference:
With early stage assets, there are continual needs for fast evaluation (TPP refinements, de-risking initial price points, etc.) to feed quick decisions that would be greatly enriched with payer feedback.
Clients leverage Quick Payer Pulse, a proprietary survey tool, to generate and quantify country-specific payer insights to support time-sensitive business needs.
Join Trinity Life Sciences’ Evidence, Value, Access and Pricing and Cell & Gene Therapy experts for a deeper look at the market access trends that will present the most impactful opportunities and challenges for life sciences organizations in 2023. This webinar will expand upon the trends discussed in the recently released white paper entitled “Global […]
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]
This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]
French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]
Senior Partner,
Evidence, Value, Access & Pricing
Ms. Martin de Bustamante’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the USA, EU5, CAN, and JPN. Ms. Martin de Bustamante has worked across the major therapeutic areas (oncology, cardiovascular, neurology, […]
Managing Director
Rob is a Managing Director in Trinity’s Evidence, Value, Access, and Pricing practice. Prior to joining Trinity, Rob was a Managing Director (Partner) at L.E.K. Consulting. Rob has 20+ years of healthcare strategy consulting experience, including ~15 years of Market Access and commercial strategy experience. His Market Access experience includes developing launch, pricing, innovative and […]
Director,
Value, Access & Pricing
Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]
Partner,
Value, Access & Pricing
Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.
Partner,
Value, Access & Pricing
Mr. Gould is a Managing Director in Trinity’s Value, Access, and Pricing practice. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould […]
Partner,
Value, Access & Pricing
John co-leads our San Francisco office and team and drives growth in our strategic advisory service offering in Pricing, Access, Reimbursement, and Contracting (PARC). Since 1999, John has been leading strategic contracting initiatives, brand planning, forecasting, and product launch strategies to inform customers’ data-driven strategic decision making with market research, quantitative analysis, and financial modeling. […]
Partner,
Evidence Strategy
An economist by training, Nandini is a Partner at Trinity Life Sciences with over two decades of experience in custom research and strategy consulting. She is seasoned at helping clients identify what evidence will be crucial in driving their product’s success, generating that evidence using publication-grade research, and pulling the insights through scientific dissemination. She […]
Partner,
Value, Access & Pricing
Mr. Hunt is a Partner in Trinity’s Value, Access, and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases, and cell and gene therapies. Prior to joining Trinity, Mr. Hunt’s engagement work at CBPartners targeted a variety of commercial business issues related […]
Partner,
Value, Access & Pricing
Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]
Partner,
Evidence Strategy
Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]
Partner, Value, Access & Pricing
& London Office Lead
Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]
Director
Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, APAC and LatAm) […]
Principal,
Value, Access & Pricing
Ms. Pikus is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Pikus led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, Ms. Pikus supported a range of qualitative and quantitative engagements to inform […]
Managing Director,
Evidence Strategy
Jeff supports pharmaceutical, device, and diagnostic companies in demonstrating and communicating the value of their products. His work is informed by broader experiences in market access and business and clinical strategy, allowing him to craft health economics and outcomes research solutions that dovetail with overall strategic plans for products across their life cycle stages. In […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.